Source - LSE Regulatory
RNS Number : 1107E
Ergomed plc
09 March 2022




John Dawson CBE Appointed to the Board as Non-Executive Director



Guildford, UK - 9 March 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has joined the Board as an independent Non-Executive Director and Chair of the Audit Committee. 


John Dawson is a highly experienced and globally respected figure in the healthcare sector. Most recently, he was Chief Executive Officer of Oxford Biomedica (LSE: OXB) where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, delivered multiple high value partnerships and successfully manufactured the life-saving Oxford/AstraZeneca COVID-19 vaccine. Under Mr. Dawson's leadership, Oxford Biomedica's success resulted in it entering the FTSE 250 index in 2020. Subsequently, in the New Year Honours List this year, he was awarded a CBE for services to UK life science, in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine.


Prior to Oxford Biomedica, Mr. Dawson held various senior executive roles including at Cephalon Pharmaceuticals where for most of his tenure he was Managing Director for Europe. Prior to this, he served as the Financial Director for Serono before its acquisition by Merck. Mr. Dawson holds a BSc in Mathematics from Swansea University and is a Chartered Accountant.


Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "As a highly regarded and well-connected figure, John is an outstanding addition to the Ergomed Board, and his wealth of international experience in the healthcare industry will be invaluable as the Company continues to grow. The resounding success of Oxford Biomedica is testament to John's strong leadership and expert knowledge of the life science sector. We look forward to utilising his network and benefiting from his extensive experience of working in the UK public markets."


John Dawson, CBE, said: "Ergomed is fast becoming a leading global pharmaceutical services provider, which has seen exceptional growth over the past few years, and which remains at a very exciting stage in its development. I look forward to working closely with the Board and Senior Management Team as we continue to build upon this momentum."


The following disclosures are made pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:


Mr. John Andrew Dawson, aged 62, holds or has held directorships in the five years preceding his appointment at Ergomed as follows:


Current Directorships:

Directorships in the past five years:

Oxford Biomedica plc

Oxford Biomedica (UK) Limited

OXB Solutions Limited


Ocquila Limited


There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.







Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)


Peel Hunt LLP (Joint Broker)

James Steel / Dr Christopher Golden                                 



Tel: +44 (0) 20 7418 8900


Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal/ Angela Gray


About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.